Medindia
Medindia LOGIN REGISTER
Advertisement

AcelRx Pharmaceuticals Reports First Quarter 2011 Financial Results

Thursday, May 12, 2011 General News
Advertisement
Initiation of Phase 3 Trial for Lead Product Candidate ARX-01 On Track for Second Half of 2011

Statements of Operations

(in thousands, except share and per share data)

Three Months Ended March 31,

2011

2010

Operating Expenses:

Research and development

$1,946

$2,761

General and administrative

1,589

672

Total operating expenses

$3,535

$3,433

Loss from operations

($3,535)

($3,433)

Net interest and other income (expense), net

331

(248)

Net loss

($3,204)

($3,681)

Net loss per share of common stock, basic and diluted

($0.30)

($5.85)

Shares used in computing net loss per share of common stock, basic and diluted

10,742,182

629,006

Sponsored Post and Backlink Submission


Latest Press Release on General News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close